Supplementary Data from KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

Lin Gao,Wenbo Zhang,Jing Zhang,Junmei Liu,Feifei Sun,Hui Liu,Jing Hu,Xin Wang,Xueli Wang,Peng Su,Shouzhen Chen,Sifeng Qu,Benkang Shi,Xueting Xiong,Weiwen Chen,Xuesen Dong,Bo Han

DOI: https://doi.org/10.1158/0008-5472.22427620.v1

2023-01-01

Abstract:Supplementary Tables

What problem does this paper attempt to address?

Supplementary Data from KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

Gao Lin,Wenbo Zhang,Jing Zhang,Junmei Liu,Fuchun Sun,Hui Liu,Jing Hu,Xin Wang,Xueli Wang,Peng Su,Shouzhen Chen,Sifeng Qu,Benkang Shi,Xueting Xiong,Weiwen Chen,Xuesen Dong,Bo Han

DOI: https://doi.org/10.1158/0008-5472.22427623.v1

2023-01-01

Abstract:supplemary figures and figure legend
KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

Lin Gao,Wenbo Zhang,Jing Zhang,Junmei Liu,Feifei Sun,Hui Liu,Jing Hu,Xin Wang,Xueli Wang,Peng Su,Shouzhen Chen,Sifeng Qu,Benkang Shi,Xueting Xiong,Weiwen Chen,Xuesen Dong,Bo Han

DOI: https://doi.org/10.1158/0008-5472.can-20-1965

IF: 11.2

2020-12-04

Cancer Research

Abstract:The new generation androgen receptor (AR) pathway inhibitor enzalutamide can prolong the survival of patients with metastatic prostate cancer. However, resistance to enzalutamide inevitably develops in these patients, and the underlying mechanisms of this resistance are not fully defined. Here we demonstrate that the kinesin family member 15 (KIF15) contributes to enzalutamide resistance by enhancing the AR signaling in prostate cancer cells. KIF15 directly bound the N-terminus of AR/AR-V7 and prevented AR/AR-V7 proteins from degradation by increasing the protein association of ubiquitin-specific protease 14 (USP14) with AR/AR-V7. In turn, the transcriptionally active AR stimulated KIF15 expression. KIF15 inhibitors alone or in combination with enzalutamide significantly suppressed enzalutamide-resistant prostate cancer cell growth and xenograft progression. These findings highlight a key role of KIF15 in enabling prostate cancer cells to develop therapy resistance to enzalutamide and rationalize KIF15 as a potential therapeutic target. SIGNIFICANCE: These findings demonstrate how reciprocal activation between KIF15 and AR contributes to enzalutamide resistance in prostate cancer and highlights cotargeting KIF15 and AR as a therapeutic strategy for these tumors.

oncology
Supplementary Figure S3 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Qing Cao,Zhengshuai Song,Hailong Ruan,Cheng Wang,Yan Xiong,Bingcheng Lin,Keshan Wang,Gong Chen,Tianbo Xu,Wen Xu,Xiong Zhang,Di Liu,Ming–Hsuan Yang,Diwei Zhou,Hongmei Yang,Ke Chen,Xiaoping Zhang

DOI: https://doi.org/10.1158/1078-0432.22473315.v1

2023-01-01

Abstract:Characterization of the enzalutamide-resistant prostate cancer cell line. A, schematic representation of the process of establishment of C4-2-ENZ-R cells. B, Cell lines were treated with enzalutamide for 48 hrs, and growth inhibition was determined by a cell viability assay. The results are shown as the mean {plus minus} SD. ***p < 0.001. C, Immunoblot detection of AR and AR-V7 protein levels in C4-2 and C4-2-ENZ-R cells. D, Cell morphology changes in C4-2 and C4-2-ENZ-R cells.
Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Qing Cao,Zhengshuai Song,Hailong Ruan,Cheng Wang,Yan Xiong,Bingcheng Lin,Keshan Wang,Gong Chen,Tianbo Xu,Wen Xu,Xiong Zhang,Di Liu,Ming–Hsuan Yang,Diwei Zhou,Hongmei Yang,Ke Chen,Xiaoping Zhang

DOI: https://doi.org/10.1158/1078-0432.22473300.v1

2023-01-01

Abstract:Primers used in quantitative polymerase chain reaction for analysis of genomic amplification
Supplementary Table 4 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Yi Liang,Sujeeve Jeganathan,Stefano Marastoni,Adam Sharp,Ines Figueiredo,Richard Marcellus,Amanda Mawson,Zvi Shalev,Aleksandra Pesic,Joan Sweet,Haiyang Guo,David Uehling,Bora Gurel,Antje Neeb,Housheng Hansen He,Bruce Montgomery,Marianne Koritzinsky,Samantha Oakes,Johann S. de Bono,Martin Gleave,Amina Zoubeidi,Bradly G. Wouters,Anthony M. Joshua

DOI: https://doi.org/10.1158/1078-0432.22484169.v1

2023-01-01

Abstract:Clinical characteristics of prostate cancer patients with matched diagnostic (archival) castration-sensitive and metastatic castration-resistant tissue biopsies
Supplementary Table S2 from birc6 Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Iris Sze Ue Luk,Raunak Shrestha,Xue Han,Yuwei Wang,Fang Zhang,Dongxin Lin,Anne Haegert,Rebecca Wu,Xinyong Dong,Colin C. Collins,Amina Zoubeidi,Martin E. Gleave,Peter W. Gout,Yuzhuo Wang

DOI: https://doi.org/10.1158/1078-0432.22464510

2023-01-01

Abstract:Gene expression changes in GPCR signalling genesets associated with ASO-6w2 treatment of LTL-313BR xenografts
Supplementary Data 2 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Jonathan R. Branch,Tammy L. Bush,Vineet Pande,Peter J. Connolly,Zhuming Zhang,Ian Hickson,Janine Ondrus,Steffen Jaensch,James R. Bischoff,Georges Habineza,Geert Van Hecke,Lieven Meerpoel,Kathryn Packman,Christopher J. Parrett,Yolanda Chong,Marco M. Gottardis,Gilles Bignan

DOI: https://doi.org/10.1158/1535-7163.22522980

2023-01-01

Abstract:Enzalutamide activates AR signaling in the absence of androgen in HepG2 transiently transfected with AR F877L and AR F877L/T878A constructs but not AR T878A only
Supplementary Tables (S1-S8) from Blocking the Feedback Loop Between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer

Chao Wang,Guang Peng,Hai Huang,Fei Liu,De-Pei Kong,Keqin Dong,Lihe Dai,Zhe Zhu,Kaijian Wang,Jing Yang,Yan‐Qiong Cheng,Xu Gao,Min Qu,Hongru Wang,Feng Zhu,Qin-Qin Tian,Dan Liú,Cao Li,Xingang Cui,Chuanliang Xu,Danfeng Xu,Yinghao Sun

DOI: https://doi.org/10.1158/1078-0432.22465379

2023-01-01

Abstract:Supplementary Tables (S1-S8)
Supplementary Table from Loss of a Negative Feedback Loop Between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance

Hongxi Wu,Linjun You,Yan Li,Zhili Zhao,Guangjiang Shi,Zhen Chen,Zhuo Wang,Xianjing Li,Shijia Du,Wanli Ye,Xiaofang Gao,Jingjing Duan,Yan Cheng,Weiyan Tao,Jinsong Bian,Jin-Rong Zhou,Qingyi Zhu,Yong Yang

DOI: https://doi.org/10.1158/0008-5472.22424598.v1

2023-01-01

Abstract:IRF8 was not frequently mutated and methylated in clinical PCa tissues and cells.
Supplementary Figure S2 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Qing Cao,Zhengshuai Song,Hailong Ruan,Cheng Wang,Yan Xiong,Bingcheng Lin,Keshan Wang,Gong Chen,Tianbo Xu,Wen Xu,Xiong Zhang,Di Liu,Ming–Hsuan Yang,Diwei Zhou,Hongmei Yang,Ke Chen,Xiaoping Zhang

DOI: https://doi.org/10.1158/1078-0432.22473318.v1

2023-01-01

Abstract:A, LNCaP cells were treated with or without DHT for 48 h. ChIP analysis of AR binding at the P1, P2, P3, P4, P5, and P6 loci in LNCaP cells. B, Whole-cell lysates of 22Rv1 cells were immunoprecipitated with anti-AR-V7 antibodies and blotted with the indicated antibodies. *p < 0.05; **p < 0.01, ***p < 0.001.
Supplementary Table 3 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Yi Liang,Sujeeve Jeganathan,Stefano Marastoni,Adam Sharp,Ines Figueiredo,Richard Marcellus,Amanda Mawson,Zvi Shalev,Aleksandra Pesic,Joan Sweet,Haiyang Guo,David Uehling,Bora Gurel,Antje Neeb,Housheng Hansen He,Bruce Montgomery,Marianne Koritzinsky,Samantha Oakes,Johann S. de Bono,Martin Gleave,Amina Zoubeidi,Bradly G. Wouters,Anthony M. Joshua

DOI: https://doi.org/10.1158/1078-0432.22484172

2023-01-01

Abstract:Compound full list of two libraries
Integrative Transcriptome Analysis Identifies Genes and Pathways Associated with Enzalutamide Resistance of Prostate Cancer

Subo Qian,Jia Xia,Hailong Liu,Yu Zhang,Lin Zhang,Yongjiang Yu

DOI: https://doi.org/10.1080/13685538.2018.1424129

2018-01-01

Abstract:BACKGROUND:Enzalutamide, a novel androgen receptor (AR) signaling inhibitor, has been widely used to increase survival in patients with castration-resistant prostate cancer. However, resistance to enzalutamide invariably develops.METHODS:To understand the underlying mechanisms of resistance to enzalutamide, we performed integrative analysis on multiple transcriptome datasets to identify those genes constantly up- or down-regulated in response to enzalutamide treatment.RESULTS:There were 703 and 581 differentially expressed genes derived from enzalutamide-sensitive and -resistant cell lines, respectively. Functional enrichment analysis on these genes demonstrated that biological processes of cell proliferation and ubiquitin mediated proteolysis pathway are specifically disturbed in sensitive cell lines but not resistant ones. Such divergence explained why enzalutamide ineffective for resistant prostate cancer.CONCLUSIONS:Taken together, the present study revealed a set of critical genes, which can provide etiologic clues as to enzalutamide-resistant prostate cancer and guide novel therapeutic approaches.
Supplementary Figure Legends from birc6 Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Iris Sze Ue Luk,Raunak Shrestha,Xue Han,Yuwei Wang,Fang Zhang,Dongxin Lin,Anne Haegert,Rebecca Wu,Xinyong Dong,Colin C. Collins,Amina Zoubeidi,Martin E. Gleave,Peter W. Gout,Yuzhuo Wang

DOI: https://doi.org/10.1158/1078-0432.22464480

2023-01-01

Abstract:Supplementary figure legends
Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

Nicola J. Clegg,John Wongvipat,James D. Joseph,Chris Tran,Samedy Ouk,Anna Dilhas,Yu Chen,Kate Grillot,Eric D. Bischoff,Ling Cai,Anna Aparicio,Steven Dorow,Vivek K. Arora,Gang Song,Qian Jiang,Hong Zhao,Guangbin Yang,Changyong Cao,John Sensintaffar,Teresa Wasielewska,Mark R. Herbert,Céline Bonnefous,Beatrice Darimont,Howard I. Scher,Peter Smith‐Jones,Mark Klang,Nicholas D. Smith,Elisa de Stanchina,Nanping Wu,Ouathek Ouerfelli,Peter J. Rix,Richard A. Heyman,Michael E. Jung,Charles L. Sawyers,Jeffrey H. Hager

DOI: https://doi.org/10.1158/0008-5472.22393727.v1

2023-01-01

Abstract:PDF file- 366K
Structural and Molecular Insights into the Mechanism of Resistance to Enzalutamide by the Clinical Mutants in Androgen Receptor (AR) in Castration-Resistant Prostate Cancer (CRPC) Patients

Abbas Khan,Yuanshen Mao,Sana Tahreem,Dong-Qing Wei,Yanjing Wang

DOI: https://doi.org/10.1016/j.ijbiomac.2022.07.058

IF: 8.2

2022-01-01

International Journal of Biological Macromolecules

Abstract:Androgen receptor (AR) is a key contributing element in the prostate cancer (PCa) instigation, progression and it is among the vastly discovered target for prostate cancer. Numerous mechanisms trigger the expansion of CRPC among which the aberrant AR gene is considered as the prime factor. Recently three essential substitutions H875Y, F877L, and T878A are reported to cause resistance to Enzalutamide. However, no detailed study is available to explore the key events that contribute to the resistance. Hence, considering the applicability of structural bioinformatics and molecular simulation-based methods in the current study, we assessed the impact of these mutations on the binding of Enzalutamide. Using a long-run simulation approach the binding stability, residues flexibility, hydrogen bonding, and protein compactness for each complex were determined to reveal the dynamic variations induced by these mutations. We discovered that the binding mode of Enzalutamide is altered by these mutations which misstarget the key residues required for the antagonistic activity. Molecular simulation of each complex revealed that the wild type H11 and H12 are more flexible moving outside and provides more volume for the ligand optimization. In the mutant complexes, the H12 remained tighter pushing out enzaluta-mide from the key residues which then essentially misstarget the correct orientation for the antagonist activity. The binding free energy (BFE) for the wild type was computed to be-59.92 +/- 0.18 kcal/mol, for H875Y the BFE was-55.92 +/- 0.18 kcal/mol,-54.82 +/- 0.15 kcal/mol for F877L and-53.87 +/- 0.18 kcal/mol for T878A, which further demonstrate that these mutations have destabilized the binding of enzalutamide. The proteins' motion and FEL further validated the aforementioned findings where the wild type reported different dynamic features than the mutant complexes. In conclusion, this study provides a structural basis for the resistance to Enzaluta-mide, which can be used to design novel effective drugs using structure-based and rationale approaches.
Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.

Qi Cao,Zhengshuai Song,Hailong Ruan,Cheng Wang,Xiong Yang,Lin Bao,Keshan Wang,Gong Cheng,TianBo Xu,Wen Xiao,Zhiyong Xiong,Di Liu,Ming Yang,Diwei Zhou,Hongmei Yang,Ke Chen,Xiaoping Zhang

DOI: https://doi.org/10.1158/1078-0432.ccr-19-0396

IF: 13.801

2019-01-01

Clinical Cancer Research

Abstract:AbstractPurpose:Emerging evidence indicates that castration-resistant prostate cancer (CRPC) is often driven by constitutively active androgen receptor (AR) or its V7 splice variant (AR-V7) and commonly becomes resistant to endocrine therapy. The aim of this work is to evaluate the function of a kinesin protein, KIF4A, in regulating AR/AR-V7 in prostate cancer endocrine therapy resistance.Experimental Design:We examined KIF4A expression in clinical prostate cancer specimens by IHC. Regulated pathways were investigated by qRT-PCR, immunoblot analysis, immunoprecipitation, and luciferase reporter and chromatin immunoprecipitation (ChIP) assays. A series of functional analyses were conducted in cell lines and xenograft models.Results:Examination of the KIF4A protein and mRNA levels in patients with prostate cancer showed that increased expression of KIF4A was positively correlated with androgen receptor (AR) levels. Patients with lower tumor KIF4A expression had improved overall survival and disease-free survival. Mechanistically, KIF4A and AR form an auto-regulatory positive feedback loop in prostate cancer: KIF4A binds AR and AR-V7 and prevents CHIP-mediated AR and AR-V7 degradation; AR binds the promoter region of KIF4A and activates its transcription. KIF4A promotes castration-sensitive and castration-resistant prostate cancer cell growth through AR- and AR-V7-dependent signaling. Furthermore, KIF4A expression is upregulated in enzalutamide-resistant prostate cancer cells, and KIF4A knockdown effectively reverses enzalutamide resistance and enhances the sensitivity of CRPC cells to endocrine therapy.Conclusions:These findings indicate that KIF4A plays an important role in the progression of CRPC and serves as a crucial determinant of the resistance of CRPC to endocrine therapy.
Supplementary Table 2 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Yi Liang,Sujeeve Jeganathan,Stefano Marastoni,Adam Sharp,Ines Figueiredo,Richard Marcellus,Amanda Mawson,Zvi Shalev,Aleksandra Pesic,Joan Sweet,Haiyang Guo,David Uehling,Bora Gurel,Antje Neeb,Housheng Hansen He,Bruce Montgomery,Marianne Koritzinsky,Samantha Oakes,Johann S. de Bono,Martin Gleave,Amina Zoubeidi,Bradly G. Wouters,Anthony M. Joshua

DOI: https://doi.org/10.1158/1078-0432.22484175.v1

2023-01-01

Abstract:List of primers used for qPCR analyses
Supplementary Fig. S4 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Yi Liang,Sujeeve Jeganathan,Stefano Marastoni,Adam Sharp,Ines Figueiredo,Richard Marcellus,Amanda Mawson,Zvi Shalev,Aleksandra Pesic,Joan Sweet,Haiyang Guo,David Uehling,Bora Gurel,Antje Neeb,Housheng Hansen He,Bruce Montgomery,Marianne Koritzinsky,Samantha Oakes,Johann S. de Bono,Martin Gleave,Amina Zoubeidi,Bradly G. Wouters,Anthony M. Joshua

DOI: https://doi.org/10.1158/1078-0432.22484196

2023-01-01

Abstract:Pharmacological screens identify BCL-2 and IKKB inhibitor that specifically targets ENZ-resistant cell lines
The Androgen Receptor Variant ARv33 Increased Enzalutamide-Resistance in Prostate Cancer Via a Unique Trans-Splicing Mechanism

Ronghao Wang,Meng Zhang,Yin Sun,Chi-Ping Huang,Jie Jin,Bosen You,Shuyuan Yeh,Chawnshang Chang

DOI: https://doi.org/10.2139/ssrn.4120409

2022-01-01

Abstract:Background: Prostate cancer (PCa) is the 2nd leading cause of cancer-related death among men in western countries, and a recently developed powerful antiandrogen enzalutamide (Enz) may extend the castration-resistant prostate cancer (CRPC) patients’ survival extra 4.8 months before development of Enz resistance.Methods: Sequencing analysis, Taqman PCR, absolute real time PCR, PDX animal model and Western blotting were used to detect our newly identified androgen receptor (AR) variant (named ARv33 due to having duplicated exon3) in various PC cell lines and human PCa samples. Genomic PCR, minigene were applied to confirm the mechanism of ARv33 generation. The biological functions of ARv33 were examined in both in vitro and in vivo experiments.Findings: ARv33 is generated via a unique trans-splicing mechanism that occurs rarely in human cells. Human clinical sample survey revealed that ARv33 is expressed in the later PCa stage. Mechanism dissection revealed that Enz/AR could function via transcriptional regulating the lncRNA-LINC00312 to promote splicing of the pre-AR transcript to induce the ARv33, which might then alter the B4GALT1 expression to increase the Enz resistance. Results from preclinical studies revealed that ARv33 could complex with ARv7 to increase the Enz resistance in vitro and targeting ARv33 with ARv33-siRNAs suppressed the EnzR tumor growth in an in vivo xenograft mice model. Together.Interpretation: This newly identified ARv33 plays key roles to alter the Enz resistance and targeting this ARv33 may provide us a new and better therapy to further suppress the CRPC that already developed the Enz resistance.Funding Information: This work was supported by George Whipple Professorship Endowment and China National Natural Science Foundation (81903113).Declaration of Interests: All authors declare there is no potential interest related to this manuscriptEthics Approval Statement: The PCa tissue samples used in the study was approved by the ethics committee of University of Rochester Medical Center (URMC). Animal experiments were performed after the approval from the URMC and the University Committee on Animal Resources (UCAR).

Supplementary Data from KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

Supplementary Data from KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

Supplementary Figure S3 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table 4 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Supplementary Table S2 from <i>birc6</i> Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Supplementary Data 2 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Supplementary Tables (S1-S8) from Blocking the Feedback Loop Between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer

Supplementary Table from Loss of a Negative Feedback Loop Between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance

Supplementary Figure S2 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table 3 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Integrative Transcriptome Analysis Identifies Genes and Pathways Associated with Enzalutamide Resistance of Prostate Cancer

Supplementary Figure Legends from <i>birc6</i> Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

Structural and Molecular Insights into the Mechanism of Resistance to Enzalutamide by the Clinical Mutants in Androgen Receptor (AR) in Castration-Resistant Prostate Cancer (CRPC) Patients

Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.

Supplementary Table 2 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Supplementary Fig. S4 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

The Androgen Receptor Variant ARv33 Increased Enzalutamide-Resistance in Prostate Cancer Via a Unique Trans-Splicing Mechanism

Supplementary Data from KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

Supplementary Data from KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

Supplementary Figure S3 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table 4 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Supplementary Table S2 from &lt;i&gt;birc6&lt;/i&gt; Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Supplementary Data 2 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Supplementary Tables (S1-S8) from Blocking the Feedback Loop Between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer

Supplementary Table from Loss of a Negative Feedback Loop Between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance

Supplementary Figure S2 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table 3 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Integrative Transcriptome Analysis Identifies Genes and Pathways Associated with Enzalutamide Resistance of Prostate Cancer

Supplementary Figure Legends from &lt;i&gt;birc6&lt;/i&gt; Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

Structural and Molecular Insights into the Mechanism of Resistance to Enzalutamide by the Clinical Mutants in Androgen Receptor (AR) in Castration-Resistant Prostate Cancer (CRPC) Patients

Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.

Supplementary Table 2 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Supplementary Fig. S4 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

The Androgen Receptor Variant ARv33 Increased Enzalutamide-Resistance in Prostate Cancer Via a Unique Trans-Splicing Mechanism

Supplementary Table S2 from <i>birc6</i> Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Supplementary Figure Legends from <i>birc6</i> Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer